Oricell moved its glypican-3 (GPC3)-targeted autologous CAR T therapy into a confirmatory registration phase II program in patients with GPC3-positive advanced hepatocellular carcinoma. The therapy, Ori-C101, is positioned as the first GPC3-directed immune cell therapy and the first CAR T approach for liver cancer to reach that stage. The company’s development plan focuses on validating efficacy in a registration-style cohort, with the intent of translating earlier signals into a more decisive regulatory evidence package. For the CAR T field, the strategic note is antigen selection and disease focus: GPC3 is a widely studied tumor-associated antigen, but platform operators are still working to prove durability and manageable safety in solid-tumor settings.